Design Therapeutics (DSGN) Preferred Stock Liabilities (2020)
Design Therapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $45.4 million for Q4 2020.
- For Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $45.4 million; the TTM value through Dec 2020 reached $45.4 million, changed N/A, while the annual FY2020 figure was $45.4 million, N/A changed from the prior year.
- Preferred Stock Liabilities for Q4 2020 was $45.4 million at Design Therapeutics, roughly flat from $45.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $45.4 million in Q1 2020 and bottomed at $45.4 million in Q1 2020.